In this study, we capitalized on the fact that GRHL2 is not detectably expressed in GBM to test whether this epithelial transcription factor can cooperate with HDACi to revert the mesenchymal phenotype and impair GBM survival. This evidence concerns the gene GRHL2 and glioblastoma.